Cognitive impairment in schizophrenia represents one of the main obstacles to clinical and
functional recovery. This expert group paper brings together experts in schizophrenia …

The monoamine model of depression has long formed the basis of drug development but
fails to explain treatment resistance or associations with stress or inflammation. Recent …

Recent data suggests that the prevalence of smoking in schizophrenia remains high. While
reports suggest that smoking increases the risk of developing schizophrenia, the potential …

Cognitive impairment represents one of the core features of schizophrenia, involves both
neurocognition and social cognition domains, and has a significant negative impact on real …

Background Few investigations have been carried out on metabolic syndrome in
antipsychotic-naïve patients with schizophrenia. Methods Our primary objective was to …

Schizophrenia is associated with a high prevalence of cigarette smoking. Neural dynamics
are spatially structured and shaped by both microscale molecular and macroscale functional …

Schizophrenia (SCZ) and bipolar disorder (BD) are severe psychiatric disorders that share
clinical features and several risk genes. Important information about their genetic …

Patients with psychotic disorders exhibit elevated mortality and morbidity rates compared to
the general population primarily due to comorbid somatic diseases. This study aims to …

Background Peripheral cytokines were found to be involved in the pathophysiology of
neurocognition in individuals with major depressive disorder (MDD). However, whether …

BackgroundCigarette smoking is associated with worse cognition and decreased cortical
volume and thickness in healthy cohorts. Chronic cigarette smoking is prevalent in …